Treatment of allergic rhinitis using mobile technology with real world data

The MASK observational pilot study

J Bousquet, S Arnavielhe, A Bedbrook, G Alexis-Alexandre, M van Eerd, R Murray, G W Canonica, M Illario, E Menditto, G Passalacqua, C Stellato, M Triggiani, P Carreiro-Martins, J Fonseca, M Morais Almeida, L Nogueira-Silva, A M Pereira, A Todo Bom, I Bosse, D Caimmi & 52 others P Demoly, P Devillier, J F Fontaine, J Just, G L Onorato, M L Kowalski, P Kuna, B Samolinski, J M Anto, J Mullol, A Valero, P V Tomazic, K C Bergmann, T Keil, L Klimek, R Mösgues, S Shamai, T Zuberbier, E Murphy, Peter McDowall, D Price, D Ryan, A Sheikh, N H Chavannes, W J Fokkens, V Kvedariene, A Valiulis, C Bachert, P W Hellings, I Kull, E Melén, M Wickman, C Bindslev-Jensen, E Eller, T Haahtela, E Valovirta, N G Papadopoulos, I Annesi-Maesano, M Bewick, S Bosnic-Anticevich, A A Cruz, G De Vries, B Gemicioglu, D Larenas-Linnemann, D Laune, E Mathieu-Dupas, R E O'Hehir, F Portejoie, V Siroux, O Spranger, O VandenPlas, A Yorgancioglu

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

BACKGROUND: Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology.

METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.

RESULTS: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control).

CONCLUSIONS: The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)1763-1774
JournalAllergy - European Journal of Allergy and Clinical Immunology
Volume73
Issue number9
Early online date15 Jan 2018
DOIs
Publication statusPublished - Sep 2018

Fingerprint

Observational Studies
Technology
Hypersensitivity
Cell Phones
Visual Analog Scale
Therapeutics
Mobile Applications
Histamine Antagonists
Malus
Rhinitis
Allergic Rhinitis
Nose
Adrenal Cortex Hormones
Asthma

Keywords

  • mHealth
  • mobile technology
  • observational study
  • rhinitis
  • treatment

Cite this

Bousquet, J., Arnavielhe, S., Bedbrook, A., Alexis-Alexandre, G., van Eerd, M., Murray, R., ... Yorgancioglu, A. (2018). Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study. Allergy - European Journal of Allergy and Clinical Immunology, 73(9), 1763-1774. https://doi.org/10.1111/all.13406
Bousquet, J ; Arnavielhe, S ; Bedbrook, A ; Alexis-Alexandre, G ; van Eerd, M ; Murray, R ; Canonica, G W ; Illario, M ; Menditto, E ; Passalacqua, G ; Stellato, C ; Triggiani, M ; Carreiro-Martins, P ; Fonseca, J ; Morais Almeida, M ; Nogueira-Silva, L ; Pereira, A M ; Todo Bom, A ; Bosse, I ; Caimmi, D ; Demoly, P ; Devillier, P ; Fontaine, J F ; Just, J ; Onorato, G L ; Kowalski, M L ; Kuna, P ; Samolinski, B ; Anto, J M ; Mullol, J ; Valero, A ; Tomazic, P V ; Bergmann, K C ; Keil, T ; Klimek, L ; Mösgues, R ; Shamai, S ; Zuberbier, T ; Murphy, E ; McDowall, Peter ; Price, D ; Ryan, D ; Sheikh, A ; Chavannes, N H ; Fokkens, W J ; Kvedariene, V ; Valiulis, A ; Bachert, C ; Hellings, P W ; Kull, I ; Melén, E ; Wickman, M ; Bindslev-Jensen, C ; Eller, E ; Haahtela, T ; Valovirta, E ; Papadopoulos, N G ; Annesi-Maesano, I ; Bewick, M ; Bosnic-Anticevich, S ; Cruz, A A ; De Vries, G ; Gemicioglu, B ; Larenas-Linnemann, D ; Laune, D ; Mathieu-Dupas, E ; O'Hehir, R E ; Portejoie, F ; Siroux, V ; Spranger, O ; VandenPlas, O ; Yorgancioglu, A. / Treatment of allergic rhinitis using mobile technology with real world data : The MASK observational pilot study. In: Allergy - European Journal of Allergy and Clinical Immunology. 2018 ; Vol. 73, No. 9. pp. 1763-1774.
@article{093071a027064b65b79f99c862481381,
title = "Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study",
abstract = "BACKGROUND: Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect {"}real world{"} everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.RESULTS: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control).CONCLUSIONS: The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved.",
keywords = "mHealth, mobile technology, observational study, rhinitis, treatment",
author = "J Bousquet and S Arnavielhe and A Bedbrook and G Alexis-Alexandre and {van Eerd}, M and R Murray and Canonica, {G W} and M Illario and E Menditto and G Passalacqua and C Stellato and M Triggiani and P Carreiro-Martins and J Fonseca and {Morais Almeida}, M and L Nogueira-Silva and Pereira, {A M} and {Todo Bom}, A and I Bosse and D Caimmi and P Demoly and P Devillier and Fontaine, {J F} and J Just and Onorato, {G L} and Kowalski, {M L} and P Kuna and B Samolinski and Anto, {J M} and J Mullol and A Valero and Tomazic, {P V} and Bergmann, {K C} and T Keil and L Klimek and R M{\"o}sgues and S Shamai and T Zuberbier and E Murphy and Peter McDowall and D Price and D Ryan and A Sheikh and Chavannes, {N H} and Fokkens, {W J} and V Kvedariene and A Valiulis and C Bachert and Hellings, {P W} and I Kull and E Mel{\'e}n and M Wickman and C Bindslev-Jensen and E Eller and T Haahtela and E Valovirta and Papadopoulos, {N G} and I Annesi-Maesano and M Bewick and S Bosnic-Anticevich and Cruz, {A A} and {De Vries}, G and B Gemicioglu and D Larenas-Linnemann and D Laune and E Mathieu-Dupas and O'Hehir, {R E} and F Portejoie and V Siroux and O Spranger and O VandenPlas and A Yorgancioglu",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "9",
doi = "10.1111/all.13406",
language = "English",
volume = "73",
pages = "1763--1774",
journal = "Allergy - European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "WILEY-BLACKWELL",
number = "9",

}

Bousquet, J, Arnavielhe, S, Bedbrook, A, Alexis-Alexandre, G, van Eerd, M, Murray, R, Canonica, GW, Illario, M, Menditto, E, Passalacqua, G, Stellato, C, Triggiani, M, Carreiro-Martins, P, Fonseca, J, Morais Almeida, M, Nogueira-Silva, L, Pereira, AM, Todo Bom, A, Bosse, I, Caimmi, D, Demoly, P, Devillier, P, Fontaine, JF, Just, J, Onorato, GL, Kowalski, ML, Kuna, P, Samolinski, B, Anto, JM, Mullol, J, Valero, A, Tomazic, PV, Bergmann, KC, Keil, T, Klimek, L, Mösgues, R, Shamai, S, Zuberbier, T, Murphy, E, McDowall, P, Price, D, Ryan, D, Sheikh, A, Chavannes, NH, Fokkens, WJ, Kvedariene, V, Valiulis, A, Bachert, C, Hellings, PW, Kull, I, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, Haahtela, T, Valovirta, E, Papadopoulos, NG, Annesi-Maesano, I, Bewick, M, Bosnic-Anticevich, S, Cruz, AA, De Vries, G, Gemicioglu, B, Larenas-Linnemann, D, Laune, D, Mathieu-Dupas, E, O'Hehir, RE, Portejoie, F, Siroux, V, Spranger, O, VandenPlas, O & Yorgancioglu, A 2018, 'Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study', Allergy - European Journal of Allergy and Clinical Immunology, vol. 73, no. 9, pp. 1763-1774. https://doi.org/10.1111/all.13406

Treatment of allergic rhinitis using mobile technology with real world data : The MASK observational pilot study. / Bousquet, J; Arnavielhe, S; Bedbrook, A; Alexis-Alexandre, G; van Eerd, M; Murray, R; Canonica, G W; Illario, M; Menditto, E; Passalacqua, G; Stellato, C; Triggiani, M; Carreiro-Martins, P; Fonseca, J; Morais Almeida, M; Nogueira-Silva, L; Pereira, A M; Todo Bom, A; Bosse, I; Caimmi, D; Demoly, P; Devillier, P; Fontaine, J F; Just, J; Onorato, G L; Kowalski, M L; Kuna, P; Samolinski, B; Anto, J M; Mullol, J; Valero, A; Tomazic, P V; Bergmann, K C; Keil, T; Klimek, L; Mösgues, R; Shamai, S; Zuberbier, T; Murphy, E; McDowall, Peter; Price, D; Ryan, D; Sheikh, A; Chavannes, N H; Fokkens, W J; Kvedariene, V; Valiulis, A; Bachert, C; Hellings, P W; Kull, I; Melén, E; Wickman, M; Bindslev-Jensen, C; Eller, E; Haahtela, T; Valovirta, E; Papadopoulos, N G; Annesi-Maesano, I; Bewick, M; Bosnic-Anticevich, S; Cruz, A A; De Vries, G; Gemicioglu, B; Larenas-Linnemann, D; Laune, D; Mathieu-Dupas, E; O'Hehir, R E; Portejoie, F; Siroux, V; Spranger, O; VandenPlas, O; Yorgancioglu, A.

In: Allergy - European Journal of Allergy and Clinical Immunology, Vol. 73, No. 9, 09.2018, p. 1763-1774.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of allergic rhinitis using mobile technology with real world data

T2 - The MASK observational pilot study

AU - Bousquet, J

AU - Arnavielhe, S

AU - Bedbrook, A

AU - Alexis-Alexandre, G

AU - van Eerd, M

AU - Murray, R

AU - Canonica, G W

AU - Illario, M

AU - Menditto, E

AU - Passalacqua, G

AU - Stellato, C

AU - Triggiani, M

AU - Carreiro-Martins, P

AU - Fonseca, J

AU - Morais Almeida, M

AU - Nogueira-Silva, L

AU - Pereira, A M

AU - Todo Bom, A

AU - Bosse, I

AU - Caimmi, D

AU - Demoly, P

AU - Devillier, P

AU - Fontaine, J F

AU - Just, J

AU - Onorato, G L

AU - Kowalski, M L

AU - Kuna, P

AU - Samolinski, B

AU - Anto, J M

AU - Mullol, J

AU - Valero, A

AU - Tomazic, P V

AU - Bergmann, K C

AU - Keil, T

AU - Klimek, L

AU - Mösgues, R

AU - Shamai, S

AU - Zuberbier, T

AU - Murphy, E

AU - McDowall, Peter

AU - Price, D

AU - Ryan, D

AU - Sheikh, A

AU - Chavannes, N H

AU - Fokkens, W J

AU - Kvedariene, V

AU - Valiulis, A

AU - Bachert, C

AU - Hellings, P W

AU - Kull, I

AU - Melén, E

AU - Wickman, M

AU - Bindslev-Jensen, C

AU - Eller, E

AU - Haahtela, T

AU - Valovirta, E

AU - Papadopoulos, N G

AU - Annesi-Maesano, I

AU - Bewick, M

AU - Bosnic-Anticevich, S

AU - Cruz, A A

AU - De Vries, G

AU - Gemicioglu, B

AU - Larenas-Linnemann, D

AU - Laune, D

AU - Mathieu-Dupas, E

AU - O'Hehir, R E

AU - Portejoie, F

AU - Siroux, V

AU - Spranger, O

AU - VandenPlas, O

AU - Yorgancioglu, A

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/9

Y1 - 2018/9

N2 - BACKGROUND: Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.RESULTS: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control).CONCLUSIONS: The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Large observational implementation studies are needed to triangulate the findings from randomized control trials (RCTs) as they reflect "real world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real life treatment of allergic rhinitis using mobile technology.METHODS: A mobile phone app (Allergy Diary, freely available Google Play and Apple App stores) collects the data of daily visual analogue scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries.RESULTS: A total of 2,871 users filled in 17,091 days of VAS in 2015 and 2016. Medications were reported for 9,634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single or multiple treatments (worst control).CONCLUSIONS: The present study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in allergic rhinitis. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings and generates new hypotheses. This article is protected by copyright. All rights reserved.

KW - mHealth

KW - mobile technology

KW - observational study

KW - rhinitis

KW - treatment

U2 - 10.1111/all.13406

DO - 10.1111/all.13406

M3 - Review article

VL - 73

SP - 1763

EP - 1774

JO - Allergy - European Journal of Allergy and Clinical Immunology

JF - Allergy - European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 9

ER -